Clinical trials: Trypanosomiasis, African
Human African Trypanosomiasis (HAT)
Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study
The aim of the study is to assess the efficacy and safety of an oral regimen of fexinidazole (once daily for 10 days) in the treatment of stage 1 and stage 2 T.b.
- Trial name
- NCT02184689
- Testing
- fexinidazole
- Where
- Democratic Republic of the Congo
- Volunteers
- 125 people
- Sponsor
- Drugs for Neglected Diseases
Trypanosomiasis, African, Gambiense Trypanosomiasis
Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense
The goal of this study is to assess efficacy and safety of acoziborole in adult participants with Trypanosoma brucei gambiense (T.b.
- Conditions
- Trypanosomiasis, African, Gambiense Trypanosomiasis, Sleeping Sickness
- Trial name
- OXA002 (NCT03087955)
- Testing
- Acoziborole
- Where
- 12 sites in Democratic Republic of the Congo, Guinea
- Volunteers
- 208 people
- Sponsor
- Drugs for Neglected Diseases
Trypanosoma Brucei Rhodesiense; Infection
A Retrospective Analysis of Suramin Treatment for Stage 1 TBR
The study will include TBR HAT patients treated with suramin between 2000 and 2020 at three sites in Uganda and Malawi A natural history cohort composed of source data from approximately 200 patients from a published…
- Trial name
- NCT06060600
- Where
- United States
- Volunteers
- 345 people
- Sponsor
- Paxmedica
Trypanosomiasis, African
A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Human African Trypanosomiasis or sleeping sickness has made a spectacular return during the last decade, and in many places the demand largely surpasses the capacities of the treatment centers.
- Trial name
- NCT00802594
- Testing
- DB289
- Where
- 2 sites in Angola, Republic of the Congo
- Volunteers
- 30 people
- Sponsor
- Immtech Pharmaceuticals, Inc
Sleeping Sickness, Trypanosomiasis, African
Screen and Treat Implementation for HAT Control
Human African Trypanosomiasis (HAT), or sleeping sickness, is one of the parasitic diseases targeted for interruption of transmission by 2030 by the WHO.
- Trial name
- NCT05645822
- Testing
- Screen&treat
- Sponsor
- Institute of Tropical Medicine, Belgium